We are live on ! Find out more
RAPP

Rapport Therapeutics
RAPP

35 hedge funds and large institutions have $593M invested in Rapport Therapeutics in 2024 Q2 according to their latest regulatory filings, with 35 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

74.47% more ownership

Funds ownership: 0% → 74.47% (+74%)

Holders
35
Holders Change
+35
Holders Change %
–
% of All Funds
0.51%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
35
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$115M
2
AVM
Arch Venture Management
Illinois
+$86.3M
3
CAM
Cormorant Asset Management
Massachusetts
+$68.1M
4
Capital International Investors
Capital International Investors
California
+$60.3M
5
JJ
Johnson & Johnson
New Jersey
+$57.8M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$116M +$115M +4,983,351 New
AVM
2
Arch Venture Management
Illinois
$86.7M +$86.3M +3,728,738 New
CAM
3
Cormorant Asset Management
Massachusetts
$68.4M +$68.1M +2,940,283 New
Capital International Investors
4
Capital International Investors
California
$60.5M +$60.3M +2,602,531 New
JJ
5
Johnson & Johnson
New Jersey
$58.1M +$57.8M +2,498,051 New
SI
6
Sofinnova Investments
California
$45.4M +$45.2M +1,951,562 New
T. Rowe Price Investment Management
7
T. Rowe Price Investment Management
Maryland
$35.7M +$35.5M +1,535,151 New
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$31.6M +$31.5M +1,360,605 New
AllianceBernstein
9
AllianceBernstein
Tennessee
$25.4M +$25.3M +1,090,858 New
PA
10
Perceptive Advisors
New York
$17.4M +$17.3M +748,183 New
Citadel Advisors
11
Citadel Advisors
Florida
$13.2M +$13.7M +592,458 New
AG
12
Artal Group
Luxembourg
$8.14M +$8.1M +350,000 New
LGM
13
Logos Global Management
California
$4.37M +$4.84M +208,910 New
WP
14
Woodline Partners
California
$3.98M +$3.96M +171,100 New
Millennium Management
15
Millennium Management
New York
$2.72M +$2.7M +116,782 New
TD Asset Management
16
TD Asset Management
Ontario, Canada
$2.36M +$2.35M +101,522 New
Manulife (Manufacturers Life Insurance)
17
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.76M +$1.75M +75,516 New
Norges Bank
18
Norges Bank
Norway
$1.63M +$1.62M +70,000 New
SVCM
19
Saturn V Capital Management
Texas
$1.63M +$1.62M +70,000 New
Vanguard Group
20
Vanguard Group
Pennsylvania
$1.63M +$1.62M +70,000 New
EAM
21
Eventide Asset Management
Massachusetts
$1.16M +$1.16M +50,000 New
LP
22
LMR Partners
United Kingdom
$1.16M +$1.16M +50,000 New
MIM
23
Monashee Investment Management
Massachusetts
$930K +$926K +40,000 New
Alyeska Investment Group
24
Alyeska Investment Group
Illinois
$808K +$804K +34,731 New
SFM
25
Soros Fund Management
New York
$698K +$695K +30,000 New
1
2

RAPP Hedge Fund Activity: Q2 2024 in Review

35 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Rapport Therapeutics (RAPP) for Q2 2024, worth a combined $593M.

Buyers outnumbered sellers: 35 funds opened new RAPP positions and 0 closed out — a net gain of 35 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $115M.

  • 35 institutional investors held Rapport Therapeutics (RAPP) as of Q2 2024, up from 0 in Q1 2024.
  • Funds reported $593M of Rapport Therapeutics stock for Q2 2024.
  • 35 funds opened new Rapport Therapeutics positions in Q2 2024 and 0 closed out, a net change of +35 holders.
  • The largest Rapport Therapeutics buyer in Q2 2024 was Fidelity Investments, an estimated $115M added.

Based on aggregated 13F filings for Q2 2024.